



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 6/14/06

Signature: *Dawn Class*

Docket No.: VASG-P01-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Krasnoperov et al.

Application No.: 10/800350

Confirmation No.: 2293

Filed: March 12, 2004

Art Unit: 1642

For: POLYPEPTIDE COMPOUNDS FOR
INHIBITING ANGIOGENESIS AND
TUMOR GROWTH

Examiner: S. E. Aeder

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicants have not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicants submit herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. VASG-P01-002. A duplicate copy of this paper is enclosed.

Dated: June 14, 2006

Respectfully submitted,

By 

Z. Angela Guo

Registration No.: 54,144

FISH & NEAVE IP GROUP, ROPES & GRAY
LLP

One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicants



PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/800350	
			Filing Date	March 12, 2004	
			First Named Inventor	Valery Krasnoperov	
			Art Unit	1642	
			Examiner Name	S. E. Aeder	
Sheet	1	of	6	Attorney Docket Number	VASG-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AE	US-2002/0136726	09-26-2002	Anderson et al.	
	AF	US-5,824,303	10-20-1998	Bartley et al.	
	AG	US-6,514,497	02-04-2003	Briskin et al.	
	AH	US-5,795,734	08-18-1998	Flanagan et al.	
	AI	US-5,770,599	06-23-1998	Gibson	
	AJ	US-6,440,954	08-27-2002	Haber et al.	
	AK	US-5,512,591	04-30-1996	Halperin et al.	
	AL	US-6,015,711	01-18-2000	Olson et al.	
	AM	US-6,579,683	06-17-2003	Wang et al.	
	AN	US-6,887,674	05-03-2005	Wang et al.	
	AO	US-6,916,625	07-12-2005	Wang et al.	
	AP	US-2005/0204412	09-15-2005	Wang et al.	
	AQ	US-6,864,227	03-08-2005	Wang et al.	
	AR	US-2006/0035328	02-16-2006	Wang et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BV	WO 98/43960	10-08-1998	American Cyanamid Company		
	BW	WO 94/11020	05-26-1994	Amgen Inc.		
	BX	WO 96/23000	08-01-1996	Amgen Inc.		
	BY	WO 96/36713	11-21-1996	Amgen Inc.		
	BZ	WO 97/23629	07-03-1997	Amrad Operations PTY. Ltd.		
	BA1	EP 633 315-A2	01-11-1995	C.I.E.M.A.T.		
	BB1	WO 99/52541	10-21-1999	California Institute of Technology		
	BC1	WO 98/45331	10-15-1998	Genentech, Inc.		
	BD1	WO 97/44453	11-27-1997	Genentech, Inc.		
	BE1	WO 97/09427	03-13-1997	Genentech, Inc.		
	BF1	WO 94/10202	05-11-1994	Genentech, Inc.		
	BG1	WO 96/13518	05-09-1996	Genentech, Inc.		
	BH1	WO 99/17796	04-15-1999	Leukosite, Inc.		
	BI1	WO 2004/091375	10-28-2004	Medimmune, Inc.		
	BJ1	WO 2005/048917	06-02-2005	Medimmune, Inc.		
	BK1	WO 2005/051307	06-09-2005	Medimmune, Inc.		
	BL1	WO 03/094859	11-20-2003	Medimmune, Inc.		
	BM1	WO 96/09384	03-28-1996	President and Fellows of Harvard College		
	BN1	WO 2004/014292	02-19-2004	Purdue Research Foundation		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1642
				Examiner Name	S. E. Aeder
Sheet	2	of	6	Attorney Docket Number	VASG-P01-002

	BO1	WO 96/03043	02-08-1996	Rutgers, the State University of New Jersey		
	BP1	WO 93/00425	01-07-1993	The Walter and Eliza Hall Institute of Medical Research		
	BQ1	EP 0999 278	05-10-2000	Universite ParisVII		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CG1	Adams, R.H., <i>et al.</i> , "Eph Receptors and Ephrin Ligands: Essential Mediators of Vascular Development," <i>Trends. Cardiovasc. Med.</i> , 10:183-188 (2000).			
	CH1	Andres, A. C. <i>et al.</i> , "Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis," <i>Oncogene</i> , 9:1461-1467 (1994).			
	CI1	Asahara, T. <i>et al.</i> , "Isolation of Putative Progenitor Endothelial Cells for Angiogenesis," <i>Science</i> , 275:964-967 (1997).			
	CJ1	Batlle, E., <i>et al.</i> , "EphB receptor activity suppresses colorectal cancer progression," <i>Nature</i> , 435(23):1126-1130 (2005).			
	CK1	Bennett, B. D. <i>et al.</i> , "Molecular cloning of a ligand for the EPH-related receptor protein-tyrosine kinase Htk," <i>Proc. Natl. Acad. Sci. USA</i> , 92:1866-1870 (1995).			
	CL1	Bennett, B.D., <i>et al.</i> , "Cloning and Characterization of HTK, a Novel Transmembrane Tyrosine Kinase of the EPH Subfamily," <i>The Journal of Biological Chemistry</i> , 269(19): 14211-14218 (1994).			
	CM1	Bergemann, A. D. <i>et al.</i> , "ELF-2, a New Member of the Eph Ligand Family Is Segmentally Expressed in Mouse Embryos in the Region of the Hindbrain and Newly Forming Somites," <i>Molecular and Cellular Biology</i> , 15(9):4921-4929 (1995).			
	CN1	Bos <i>et al.</i> , "PD153035, a Tyrosine Kinase Inhibitor, Prevents Epidermal Growth Factor Receptor Activation and Inhibitors Growth of Cancer Cells in a Receptor Number-dependent Manner," <i>Clinical Cancer Research</i> , 3:2099-2106 (1997).			
	CO1	Boyd, W.A., <i>et al.</i> , "Isolation and Characterization of a Novel Receptor-type Protein Tyrosine Kinase (hek) from a Human Pre-B Cell Line," <i>The Journal of Biological Chemistry</i> , 267(5):3262-3267 (1992).			
	CP1	Brehmer <i>et al.</i> , "Cellular Targets of Gefitinib," <i>Cancer Research</i> , 65(2):379-382 (2005).			
	CQ1	Bruckner <i>et al.</i> , "Tyrosine Phosphorylation of Transmembrane Ligands for Eph Receptors," <i>Science</i> , 275:1640-1643 (1997).			
	CR1	Chang, M.W., <i>et al.</i> , "Adenovirus-Mediated Over-Expression of the Cyclin/Cyclin-Dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty," <i>J. Clin. Invest.</i> , 96:2260-2268 (1995).			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1642
				Examiner Name	S. E. Aeder
				Attorney Docket Number	VASG-P01-002
Sheet	3	of	6		

	CS1	Coffman, K.T., <i>et al.</i> , "Differential EphA2 Epitope Display on Normal versus Malignant Cells," <i>Cancer Research</i> , 63:7907-7912 (2003).	
	CT1	Dodelet, V.C. <i>et al.</i> , "Eph Receptors and Ephrin Ligands: Embryogenesis to Tumorigenesis," <i>Oncogene</i> , 19(49): 5614-19 (2000).	
	CU1	Durbin, L., <i>et al.</i> , "Eph signaling is required for segmentation and differentiation of the somites," <i>Genes & Development</i> , 12:3096-3109 (1998).	
	CV1	Easty <i>et al.</i> , "Abnormal Protein Tyrosine Kinase Gene Expression During Melanoma Progression and Metastasis," <i>Int. J. Cancer</i> , 60:129-136 (1995).	
	CW1	Easty <i>et al.</i> , "Cytokine B61 as a growth factor for metastatic melanomas and increasing expression of its receptor ECK during melanoma progression," <i>Proceedings of the American Association for Cancer Research</i> , 35(356) (1994) abstract only.	
	CX1	Easty, <i>et al.</i> , "Expression of Eck and Lerk-1 During Melanoma Progression," <i>P137 St. George's Hospital Medical School, London, JK and Western Infirmary, Glasgow, UK, Collection of the National Library of Medicine by a third party.</i>	
	CY1	Feldman, L.J., <i>et al.</i> , "Perspectives of Arterial Gene Therapy for the Prevention of Restenosis," <i>Cardiovasc. Res.</i> , 32:194-207 (1996).	
	CZ1	Folkman <i>et al.</i> , "Angiogenic Factors," <i>Science</i> , 235:442-447 (1987).	
	CA2	Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," <i>Nature Medicine</i> , 1: 27-31, (1995).	
	CB2	Folkman, J. <i>et al.</i> , "Blood Vessel Formation: What Is Its Molecular Basis?" <i>Cell</i> , 87:1153-1155 (1996).	
	CC2	Folkman, J., "Angiogenic Therapy of the Human Heart," <i>Circulation</i> , 97(7): 628-29 (1998).	
	CD2	Folkman, J., "Antiangiogenic Gene Therapy," <i>Proc. Natl. Acad. Sci. USA.</i> , 95:9064-66 (1998).	
	CE2	Folkman, J., "Fighting Cancer by Attacking Its Blood Supply," <i>Sci. Am.</i> , 275(3): 150-54 (1996).	
	CF2	Gale, N.W. <i>et al.</i> , "Growth Factors Acting Via Endothelial Cell-Specific Receptor Tyrosine Kinases: VEGFs, Angiopoietins, and Ephrins in Vascular Development," <i>Genes Dev.</i> , 13:1055-66 (1999).	
	CG2	Gale, N.W., <i>et al.</i> , "Ephrin-B2 Selectively Marks Arterial Vessels and Neovascularization Sites in the Adult, with Expression in Both Endothelial and Smooth-Muscle Cells," <i>Dev. Biol.</i> , 230: 151-160 (2001).	
	CH2	GenBank Accession No. P52803.	
	CI2	Genetech's Response to Final Office Action on U.S. Patent Application Serial No. 09/442,898, filed March 29, 2002.	
	CJ2	Glassberg <i>et al.</i> , "Cultured endothelial cells derived from the human iliac arteries," <i>In Vitro</i> , 18:859-866 (1982).	
	CK2	Goetz <i>et al.</i> , "Long-term serial cultivation of arterial and capillary endothelium from adult bovine brain," <i>In Vitro Cellular and Developmental Biology</i> , 21:172-180 (1985).	
	CL2	Guzman, R.J., <i>et al.</i> , "In Vivo Suppression of Injury-Induced Vascular Smooth Muscle Cell Accumulation Using Adenovirus-Mediated Transfer of the Herpes Simplex Virus Thymidine Kinase Gene," <i>Proc. Natl. Acad. Sci. USA</i> , 91:10732-10736 (1994).	
	CM2	Hafner <i>et al.</i> , "Differential Gene Expression of Eph Receptors and Ephrins in Benign Human Tissues and Cancers," <i>Clinical Chemistry</i> , 50(3):490-499 (2004).	
	CN2	Hafner, <i>et al.</i> , "Loss of Eph B6 expression in metastatic melanoma," <i>International Journal of Oncology</i> , 23:1553-1559 (2003).	
	CO2	Hausner, C., "Organogenesis Vascular Graft Becomes Physiologically-Responsive Living	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/800350	
			Filing Date	March 12, 2004	
			First Named Inventor	Valery Krasnoperov	
			Art Unit	1642	
			Examiner Name	S. E. Aeder	
Sheet	4	of	6	Attorney Docket Number	VASG-P01-002

		Tissue After Implantation [online], " <i>Nature Biotechnol.</i> , (1999).	
CP2		Henkemeyer, M., <i>et al.</i> , "Nuk Controls Pathfinding of Commissural Axons in the Mammalian Central Nervous System," <i>Cell</i> , 86:35-46 (1996).	
CQ2		Indolfi, C., <i>et al.</i> , "Inhibition of Cellular ras Prevents Smooth Muscle Cell Proliferation After Vascular Injury In Vivo," <i>Nature Med.</i> , 1(6):541-545 (1995).	
CR2		Kenyon, B.M., <i>et al.</i> , "A Model of Angiogenesis in the Mouse Cornea," <i>Invest Ophthalmol. Vis. Sci.</i> , 37:1625-1632 (1996).	
CS2		Keogh, M-C, <i>et al.</i> , "Design of a Muscle Cell-Specific Expression Vector Utilising Human Vascular Smooth Muscle ? - Actin Regulatory elements," <i>Gene Therapy</i> , 6:616-628 (1999).	
CT2		Lackmann, <i>et al.</i> , "Distinct Subdomains of the EphA3 Receptor Mediate Ligand Binding and Receptor Dimerization," <i>The Journal of Biological Chemistry</i> , 273 (32):20228-20237 (1998).	
CU2		Li, J., <i>et al.</i> , "Expression of the SM22x Promoter in Transgenic Mice Provides Evidence for Distinct Transcriptional Regulatory Programs in Vascular and Visceral Smooth Muscle Cells," <i>J. Cell Biol.</i> , 132:849-59 (1996).	
CV2		Lin, P., <i>et al.</i> , "Antiangiogenic Gene Therapy Targeting the Endothelium-Specific Receptor Tyrosine Kinase Tie2," <i>Proc. Natl. Acad. Sci., USA</i> , 95:8829-8834 (1998).	
CW2		Magal, <i>et al.</i> , "B61, a Ligand for the Eck Receptor Protein-Tyrosine Kinase, Exhibits Neurotrophic Activity in Cultures of Rat Spinal Cord Neurons," <i>Journal of Neuroscience Research</i> , 43:735-744 (1996).	
CX2		Maru, <i>et al.</i> , "Evolution, Expression, and Chromosomal Location of a Novel Receptor Tyrosine Kinase Gene, eph," <i>Molecular and Cellular Biology</i> , 8(9):3770-3776 (1998).	
CY2		Maru, <i>et al.</i> , "Overexpression confers an oncogenic potential upon the eph gene," <i>Oncogene</i> , 5:445-447 (1990).	
CZ2		Mellitzer, G., <i>et al.</i> , "Eph Receptors and Ephrins Restrict Cell Intermingling and Communication," <i>Nature</i> , 400:77-82 (1999).	
CA3		Nakanuma, Y. <i>et al.</i> , "Succinylated Wheat Germ Agglutinin Lectin Binding in Intrahepatic Vessels: A New Histochemical Tool," <i>Arch. Pathol. Lab. Med.</i> , 117:809-811 (1993).	
CB3		Niklason, L.E., <i>et al.</i> , "Functional Arteries Grown In Vitro," <i>Science</i> , 284:489-493 (1999).	
CC3		Niklason, L.E., <i>et al.</i> , "Morphologic and Mechanical Characteristics of Engineered Bovine Arteries," <i>J. Vasc. Surg.</i> , 33:628-638 (2001).	
CD3		Nikolova, <i>et al.</i> , "Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis," <i>Journal of Cell Science</i> , 111:2741-2751 (1998).	
CE3		Ogle <i>et al.</i> , "The Role of Vascular Smooth Muscle Cell Integrins in the Compaction and Mechanical Strengthening of a Tissue-Engineered Blood Vessel," <i>Tissue Engineering</i> , 5(4):387-402 (1999).	
CF3		Orioli, D., <i>et al.</i> , "Sek4 and Nuk Receptors Cooperate in Guidance of Commissural Axons and in Palate Formation," <i>Embo J.</i> , 15(22):6035-6049.	
CG3		Pandey <i>et al.</i> , "Role of B61, the ligand for the eck receptor tyrosine kinase, in TNF- α -induced angiogenesis" <i>Science</i> , 268:567-569 (1996).	
CH3		Parangi <i>et al.</i> , "Antiangiogenic therapy of transgenic mice impairs <i>de novo</i> tumor growth," <i>Proc. Natl. Acad. Sci. USA</i> , 93:2002-2007 (1996).	
CI3		Peng <i>et al.</i> , "Regulation of Ca ²⁺ -activated K ⁺ channels in pulmonary vascular smooth muscle cells: role of nitric oxide," <i>J. Applied Physiol.</i> , 81:1264-1272 (1996).	
CJ3		Presta <i>et al.</i> , "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders," <i>Cancer Research</i> , 57:4593-	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/800350	
			Filing Date	March 12, 2004	
			First Named Inventor	Valery Krasnoperov	
			Art Unit	1642	
			Examiner Name	S. E. Aeder	
Sheet	5	of	6	Attorney Docket Number	VASG-P01-002

		4599 (1997).	
CK3	Ramchandran et al., "Metalloprotease-mediated cleavage secretion of pulmonary ACE by vascular endothelial and kidney epithelial cells," <i>Am. J. Physiology</i> , 271:H744-751 (1996).		
CL3	Risau, W., "Mechanisms of angiogenesis," <i>Nature</i> , 386:671-674 (1997).		
CM3	Shepard, et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic," <i>Journal of Clinical Immunology</i> , 11(3):117-127 (1991).		
CN3	Simonet, S., et al., "Venous and Arterial Endothelial Cells Respond Differently to Thrombin and its Endogenous Receptor Agonist," <i>European Journal of Pharmacology</i> , 216:135-137 (1992).		
CO3	Simons, M., et al., "Antisense c-myc Oligonucleotides Inhibit Intimal Arterial Smooth Muscle Cell Accumulation In Vivo," <i>Nature</i> , 359(6390):67-70 (1992).		
CP3	Stein, E. et al., "Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses," <i>Genes & Development</i> , 12:667-678 (1998).		
CQ3	Stein, E. et al., "Nck Recruitment to Eph Receptor, EphB1/ELK, Couples Ligand Activation to c-Jun Kinase," <i>The Journal of Biological Chemistry</i> , 273(3):1303-1308 (1998).		
CR3	Sturz, et al., "EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration," <i>Biochemical and Biophysical Research Communications</i> , 313:80-88 (2004).		
CS3	Sunasse, et al., "Tumour angiogenesis: Hitting cancer where it hurts," <i>Current Biology</i> , 7(5):R282-R285 (1997).		
CT3	Tallquist, M.D., et al., "Growth Factor Signaling Pathways in Vascular Development," <i>Oncogene</i> , 18(55):7917-7932 (1999).		
CU3	The Eph Nomenclature Committee, "Unified Nomenclature for Eph Family Receptors and Their Ligands, the Ephrins," <i>Cell</i> , 90:403-404 (1997).		
CV3	Thurston et al., "Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding," <i>American Journal of Physiology</i> , 271:H2547-H2562 (1996).		
CW3	Tsui, L.V., et al., "p27-p16 Fusion Gene Inhibits Angioplasty-Induced Neointimal Hyperplasia and Coronary Artery Occlusion," <i>Circ. Res.</i> , 89:323-328 (2001).		
CX3	Twardowski et al., "Clinical trials of antiangiogenic agents," <i>Current Opinion in Oncology</i> , 9:584-589 (1997).		
CY3	van de Wiel et al., "Factors that define the susceptibility of endothelial cells to tumor necrosis factor and lipid A," <i>Immunopharmacology</i> , 23:49-56 (1992).		
CZ3	Vasgene Therapeutics, Inc., "Statement of Grounds of Opposition," In the Matter of European Patent No. 1135153 (EP-B-1135153), (2006).		
CA4	Vector Laboratories, "Wheat Germ Agglutinin (WGA)," [online]		
CB4	von der Leyen, H.E., et al., "Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene," <i>Proc. Natl. Acad. Sci.</i> , 92:1137-1141 (1995).		
CC4	Wang et al., "Molecular Distinction and Angiogenic Interactions Between Embryonic Arteries and Veins Revealed By EphrinB2 and Its Receptor EphB4," <i>Circulation: Melvin L. Marcus Young Investigator Award</i> , Abstract 341.		
CD4	Wang, H. U. et al., "Eph Family Transmembrane Ligands Can Mediate Repulsive Guidance of Trunk Neural Crest Migration and Motor Axon Outgrowth," <i>Neuron</i> , 18:383-396 (1997).		
CE4	Waugh, J.M., et al., "Thrombomodulin Overexpression to Limit Neointima Formation," <i>Circulation</i> , 102:332-337 (2000).		
CF4	Winlaw, "Angiogenesis in the Pathobiology and Treatment of Vascular and Malignant		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/800350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1642
				Examiner Name	S. E. Aeder
				Attorney Docket Number	VASG-P01-002
Sheet	6	of	6		

		Diseases," <i>Ann. Thorac. Surg.</i> , 64:1204-1211 (1997).	
	CG4	Xu, <i>et al.</i> , "Function of the Eph-related kinase rtk1 in patterning of the zebrafish forebrain," <i>Nature</i> , 381:19-322 (1996).	
	CH4	Yamamoto <i>et al.</i> , "Differences in Cellular Responses to Mitogens in Arterial Smooth Muscle Cells Derived From Patients With Moyamoya Disease," <i>Stroke</i> , 29:1188-1193 (1998).	
	CI4	Yancopoulos, G. D. <i>et al.</i> , "Vasculogenesis, Angiogenesis, and Growth Factors: Ephrins Enter the Fray at the Border," <i>Cell</i> , 93:661-664 (1998).	
	CJ4	Yuan, <i>et al.</i> , "Syndecan-1 up-regulated by ephrinB2/EphB4 plays dual roles in inflammatory angiogenesis," <i>Blood</i> , 104(4):1025-1033 (2004).	
	CK4	Zetter, "Angiogenesis and Tumor Metastasis," <i>Annu. Rev. Med.</i> , 49:407-424, (1998).	
	CL4	Zhang, X-Q, <i>et al.</i> , "Stromal Cells Expressing ephrin-B2 Promote the Growth and Sprouting of Ephrin-B2+ Endothelial Cells," <i>Blood</i> , 98:1028-37 (2001).	
	CM4	Zhou, "The Eph Family Receptor and Ligands," <i>Pharmacol. Ther.</i> , 77(3) 151-181 (1998).	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



IFW

PTO/SB/17 (12-04v2)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL For FY 2005		Complete if Known	
		Application Number	10/800350
		Filing Date	March 12, 2004
		First Named Inventor	Valery Krasnoperov
		Examiner Name	S. E. Aeder
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	Art Unit	1642	
TOTAL AMOUNT OF PAYMENT	(\$) 180.00	Attorney Docket No.	VASG-P01-002

METHOD OF PAYMENT (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 18-1945
Deposit Account Name: Fish & Neave IP Group, Ropes & Gray LLP	
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
	FILING FEES		SEARCH FEES		EXAMINATION FEES		
		Small Entity		Small Entity		Small Entity	
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees Paid (\$)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
Fee Description	Fee (\$)	Small Entity Fee (\$)					
Each claim over 20 (including Reissues)	50	25					
Each independent claim over 3 (including Reissues)	200	100					
Multiple dependent claims	360	180					
Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims			
		x		Fee (\$)	Fee Paid (\$)		
Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)				
		x					
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)			
	- 100 =	/50	(round up to a whole number) x				
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)							Fees Paid (\$)
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement							180.00

SUBMITTED BY			
Signature		Registration No. (Attorney/Agent)	54,144
Name (Print/Type)	Z. Angela Guo	Telephone	(617) 951-7546
		Date	June 14, 2006

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: 6/14/06	Signature: Dawn Class, D-Class